<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253172</url>
  </required_header>
  <id_info>
    <org_study_id>NL60825.078.17</org_study_id>
    <secondary_id>MEC-2017-226</secondary_id>
    <secondary_id>CP16.01</secondary_id>
    <nct_id>NCT03253172</nct_id>
  </id_info>
  <brief_title>Potassium Supplementation in CKD</brief_title>
  <acronym>K+ in CKD</acronym>
  <official_title>Renoprotective Effects of Potassium Supplementation in Chronic Kidney Disease (CKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current high-sodium, low-potassium diet contributes to the high prevalence of high blood
      pressure (hypertension). Indeed, the anti-hypertensive effects of potassium supplementation
      are well-established. Hypertension is even more prevalent and resistant in patients with
      chronic kidney disease (CKD) and contributes to further decline in kidney function. Four
      recent epidemiological studies (published 2014 - 2016) showed that higher dietary potassium
      intake was associated with better renal outcomes. All studies recommended an intervention
      study with potassium supplementation in patients with CKD, but this has not been performed.
      The aim of this study is to study the renoprotective effect of potassium supplementation in
      patients with CKD (stage 3b or 4, i.e. estimated glomerular filtration rate [eGFR] 15 - 45
      ml/min/1.73 m2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>≥ 30% decrease in eGFR</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope analysis (change in eGFR in ml/min/1.73 m2/year)</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doubling in serum creatinine or end-stage renal disease</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression to next CKD or albuminuria class</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory (24-hour) blood pressure</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour albuminuria</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event</measure>
    <time_frame>Two years</time_frame>
    <description>Coronary heart disease death, fatal myocardial infarction, fatal stroke and other cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, unstable angina, resuscitated cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyperkalemia</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-pro-BNP</measure>
    <time_frame>Two years</time_frame>
    <description>Volume marker 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioimpedance measures</measure>
    <time_frame>Two years</time_frame>
    <description>Volume marker 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse-wave velocity</measure>
    <time_frame>Two years</time_frame>
    <description>Cardiovascular marker 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitive CRP</measure>
    <time_frame>Two years</time_frame>
    <description>Cardiovascular marker 2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">532</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Potassium Depletion</condition>
  <condition>Hypertension</condition>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium Chloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Chloride</intervention_name>
    <description>Two potassium supplements with varying anions.</description>
    <arm_group_label>Potassium Chloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Citrate</intervention_name>
    <description>Potassium Citrate</description>
    <arm_group_label>Potassium Citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD 3b or 4 (45 - 15 ml/min/1.73 m2)

          -  Δ eGFR (as estimated by the CKD-EPI equation) &gt; 2 ml/min/1.73 m2/year (in preceding ≥
             1 year with at least 3 measurements)

          -  Hypertension (defined as office blood pressure &gt; 140/90 mmHg or use of
             anti-hypertensive medication)

        Exclusion Criteria:

          -  Hyperkalemia (serum potassium &gt; 5.5 mmol/l) at study visit V0

          -  Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor blockers,
             potassium-sparing diuretics, or oral potassium binders.

          -  Patients with previous history of ventricular cardiac arrhythmia

          -  Patients with a life expectancy &lt; 6 months

          -  Expected initiation of renal replacement therapy &lt; 2 years

          -  Incapacitated subjects

          -  Women who are pregnant, breastfeeding or consider pregnancy in the coming 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewout J Hoorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ewout J Hoorn, MD, PhD</last_name>
    <phone>+31107040704</phone>
    <email>e.j.hoorn@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liffert Vogt, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin H De Borst, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joris I Rotmans, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewout J Hoorn</last_name>
      <phone>+31107040704</phone>
    </contact>
    <investigator>
      <last_name>Martin Gritter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ewout Hoorn</investigator_full_name>
    <investigator_title>Coordinating PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
    <mesh_term>Hypokalemia</mesh_term>
    <mesh_term>Potassium Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

